These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34241685)

  • 41. Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).
    Rossanese M; Novara G; Challacombe B; Iannetti A; Dasgupta P; Ficarra V
    BJU Int; 2015 Jan; 115(1):32-40. PubMed ID: 24602031
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Silodosin to facilitate passage of ureteral stones: a multi-institutional, randomized, double-blinded, placebo-controlled trial.
    Sur RL; Shore N; L'Esperance J; Knudsen B; Gupta M; Olsen S; Shah O
    Eur Urol; 2015 May; 67(5):959-64. PubMed ID: 25465978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
    Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E
    Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of Silodosin in Expulsive Therapy for Distal Ureteral Stones: A Randomized Double-blinded Controlled Trial.
    Wang CJ; Tsai PC; Chang CH
    Urol J; 2016 Jun; 13(3):2666-71. PubMed ID: 27351320
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).
    Drake MJ; MacDiarmid S; Chapple CR; Esen A; Athanasiou S; Cambronero Santos J; Mitcheson D; Herschorn S; Siddiqui E; Huang M; Stoelzel M
    Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28419650
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
    Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
    Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Profile of mirabegron in the treatment of overactive bladder: place in therapy.
    Sharaf A; Hashim H
    Drug Des Devel Ther; 2017; 11():463-467. PubMed ID: 28255232
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sexual intercourse as a new option in the medical expulsive therapy of distal ureteral stones in males: a prospective, randomized, controlled study.
    Bayraktar Z; Albayrak S
    Int Urol Nephrol; 2017 Nov; 49(11):1941-1946. PubMed ID: 28803386
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and Safety of Naftopidil in the Medical Expulsion Therapy for Distal Ureteral Stone: A Systematic Review and Meta-Analysis.
    Li J; Tang Z; Gao L; Li J; Qin F; Yuan J
    J Endourol; 2017 May; 31(5):427-437. PubMed ID: 28306333
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction.
    Nitti VW; Rosenberg S; Mitcheson DH; He W; Fakhoury A; Martin NE
    J Urol; 2013 Oct; 190(4):1320-7. PubMed ID: 23727415
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Urinary incontinence: Patient-reported outcome measures favour use of mirabegron in patients with OAB.
    Sidaway P
    Nat Rev Urol; 2015 Nov; 12(11):593. PubMed ID: 26345211
    [No Abstract]   [Full Text] [Related]  

  • 52. Efficacy of mirabegron for ureteral stones: a systematic review with meta-analysis of randomized controlled trials.
    Wang Z; Chi J; Liu Y; Wu J; Cui Y; Yang C
    Front Pharmacol; 2023; 14():1326600. PubMed ID: 38178860
    [No Abstract]   [Full Text] [Related]  

  • 53. Silodosin versus tamsulosin as medical expulsive therapy for distal ureteral stones: a prospective randomized study.
    Dell'Atti L
    Urologia; 2015; 82(1):54-7. PubMed ID: 25198942
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: SYNERGY II study.
    Alcántara Montero A
    Actas Urol Esp (Engl Ed); 2019; 43(1):51-52. PubMed ID: 30025617
    [No Abstract]   [Full Text] [Related]  

  • 55. Efficacy of tamsulosin in the management of lower ureteral stones: a randomized double-blind placebo-controlled study of 100 patients.
    Al-Ansari A; Al-Naimi A; Alobaidy A; Assadiq K; Azmi MD; Shokeir AA
    Urology; 2010 Jan; 75(1):4-7. PubMed ID: 20109697
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of low dose tamsulosin in medical expulsive therapy for ureteral stones in Japanese male patients: a randomized controlled study.
    Kaneko T; Matsushima H; Morimoto H; Tsuzaka Y; Homma Y
    Int J Urol; 2010 May; 17(5):462-5. PubMed ID: 20202002
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder.
    Blais AS; Nadeau G; Moore K; Genois L; Bolduc S
    Eur Urol; 2016 Jul; 70(1):9-13. PubMed ID: 26876327
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medical expulsive treatment of distal-ureteral stones using tamsulosin: a single-center experience.
    De Sio M; Autorino R; Di Lorenzo G; Damiano R; Giordano D; Cosentino L; Pane U; Di Giacomo F; Mordente S; D'Armiento M
    J Endourol; 2006 Jan; 20(1):12-6. PubMed ID: 16426124
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of the efficiency of tamsulosin and Rowatinex in patients with distal ureteral stones: a prospective, randomized, controlled study.
    Aldemir M; Uçgül YE; Kayıgil O
    Int Urol Nephrol; 2011 Mar; 43(1):79-83. PubMed ID: 20535638
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A second cycle of tamsulosin in patients with distal ureteric stones: a prospective randomized trial.
    Porpiglia F; Fiori C; Ghignone G; Vaccino D; Billia M; Morra I; Ragni F; Scarpa RM
    BJU Int; 2009 Jun; 103(12):1700-3. PubMed ID: 19159408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.